Ms4a7 expression in cDC1s determines cross-presentation and antitumor immunity

Area of Science:

• Immunology
• Cell Biology
• Cancer Research

Background:

• Conventional type 1 dendritic cells (cDC1s) are crucial for initiating adaptive immune responses by priming CD8+ T cells.
• Understanding how tumor antigens are processed by cDC1s to activate CD8+ T cell immunity is vital for cancer immunotherapy.
• The molecular mechanisms governing cDC1 cross-presentation of tumor antigens remain incompletely understood.

Purpose of the Study:

• To investigate the role of Ms4a7 in cDC1 function, particularly in antigen cross-priming.
• To determine the impact of Ms4a7 deficiency on CD8+ T cell responses in vivo.
• To explore the clinical relevance of MS4A7 expression in human cancers.

Main Methods:

• Utilized Ms4a7 knockout (Ms4a7-/-) mouse models to assess cDC1 development, turnover, and T cell priming capacity.
• Analyzed gene expression of MS4A7 in human tumor samples and draining lymph nodes (dLNs).
• Correlated MS4A7 expression with patient survival data.

Main Results:

• Ms4a7 expression is upregulated in cDC1s upon antigen uptake or stimulation and is essential for their cross-priming ability.
• Ms4a7-/- mice exhibited impaired antigen-specific CD8+ T cell priming following infection or tumor development, despite normal cDC1 development.
• MS4A7 was found to be expressed in a subset of human cDC1s, enriched in dLNs, and associated with patient survival outcomes.

Conclusions:

• Ms4a7 plays a critical role in the cross-presentation function of cDC1s.
• Ms4a7 is essential for effective antitumor CD8+ T cell responses.
• MS4A7 represents a potential biomarker and therapeutic target in cancer immunology.